Unaudited Financial Results for quarter and nine months ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech Ltd reported unaudited financial results for Q3 FY26 (quarter ended 31 Dec 2025) and the nine-month period. Revenue from operations for Q3 stood at Rs 510 lakh, down from Rs 605 lakh in the previous quarter (Q2 FY26), and the company posted a net loss of Rs 266 lakh for the quarter versus Rs 270 lakh loss in Q2. For the nine months ended Dec 2025, revenue from operations was Rs 1,505 lakh (vs Rs 1,532 lakh in the same period last year), and the company reported a net loss of Rs 898 lakh, an improvement from a loss of Rs 1,107 lakh in 9M FY25. EPS for the quarter was negative Rs 0.17. The statutory auditor (Rajiv Udai & Associates) issued an unmodified limited review report with no qualifications.
The company continues to operate at a loss, though the magnitude of losses has narrowed compared to the prior year. Sequential revenue declined from Q2 to Q3, which may concern short-term investors, but the year-on-year loss reduction is a modest positive signal for shareholders.